Profile

Specialty pharma meets M&A competence.

CHEPLAPHARM is a family-owned pharmaceutical company, headquartered in Germany. We offer our branded products on a global level.

By focusing on an internationally oriented Buy and Build Strategy, we generate annually increasing growth rates. The close collaboration with our business partners and our international subsidiaries allows CHEPLAPHARM to successfully realize its corporate strategy.

  • 1998

    Pharma manager Kurt Teubner establishes... »

  • 2003

    The BRAUN family acquires the business with an ... »

  • 2003

    Sebastian F. Braun succeeds as Chief Executive ... »

  • 2004

    The products Caye® and Talidat® are acquired ... »

  • 2006

    Acquisition of ALDACTONE®, LANITOP® ... »

  • 2006

    In April, CHEPLAPHARM takes over Ky-Cor F ... »

  • 2007

    CHEPLAPHARM achieves an annual turnover of 3 million ... »

  • 2007

    Takeover of Aponal® in Germany from ... »

  • 2008

    In May, CHEPLAPHARM purchases Aquaphor® ... »

  • 2008

    In June, CHEPLAPHARM obtains the rights for Gelusil ... »

  • 2008

    CHEPLAPHARM acquires the traditional Hamburg-based ... »

  • 2008

    The generated sales of nearly 8 million EURO ... »

  • 2009

    CHEPLAPHARM continues its growth strategy. Six ... »

  • 2010

    September - With the acquisition of DISTRANEURIN® ... »

  • 2011

    In July, CHEPLAPHARM attains the rights for a ...  »

  • 2011

    Through our successful merger and acquisition ...  »

  • 2012

    100 percent takeover of company shares of the ...  »

  • 2012

    In March, CHEPLAPHARM inaugurates its new ...  »

  • 2012

    With the takeover of VESANOID® ...  »

  • 2013

    Bianca Y. Juha, sister of CEO Sebastian F. Braun ... »

  • 2013

    In September, CHEPLAPHARM acquires Reisegold®  ... »

  • 2013

    Along with its subsidiaries, CHEPLAPHARM attains an ... »

  • 2014

    The takeover of all company shares from New York-based ... »

  • 2014

    CHEPLAPHARM acquires the worldwide rights ... »

  • 2014

    With more than 25 years of experience ... »

  • 2014

    Especially our European presence is notably ... »

  • 2014

    At the end of the year, CHEPLAPHARM opens the ... »

  • 2015

    At the beginning of the year, CHEPLAPHARM ... »

  • 2015

    In January, we expand our product portfolio in Italy ... »

  • 2015

    In November, CHEPLAPHARM strengthens its ... »

  • 2016

    At the very beginning of the year, CHEPLAPHARM ... »

  • 2016

    End of September, contracts for the worlwide Rights of Antiadipositum XENICAL® ... »

  • 2016

    CHEPLAPHARM concludes with an annual turnover of 121 million EURO... »

  • 2017

    The Closing for DILATREND® was completed in... »

  • 2017

    Based on a marketing and distribution agreement with Orexigen... »

  • 2017

    September - More than 150 employees from twelve different nations ... »

  • 2017

    Per 01.12.2017, CHEPLAPHARM includes the OTC product range Calcivit D®/Calcivit D® Forte... »

  • 2017

    With annual sales of 223 million euros, CHEPLAPHARM achieved... »

  • 2018

    The Closing for the antiviral agent CYMEVENE® took place... »

  • 2018

    Per 03.01.2018, CHEPLAPHARM takes over the products KONAKION® MM,... »

  • 2018

    CHEPLAPHARM further enhances its portfolio in the Cardiology area... »

  • 2018

    By acquiring the worldwide rights (except USA) for the product VISUDYNE®... »

  • 2018

    Since its foundation, CHEPLAPHARM has pursued a successful and sustainable... »

  • 2018

    CHEPLAPHARM secures the products rights for ATACAND® and ATACAND® Plus... »

  • 2018

    Per August, CHEPLAPHARM takes over the global rights for QUESTRAN®... »

  • 2018

    September - CHEPLAPHARM continues its successful expansion strategy... »

  • 2018

    From October, the company headquarters is officially relocated... »

1998

Pharma manager Kurt Teubner establishes CHEPLAPHARM in Freiburg, Germany. The company’s name originates from one of the first products in our portfolio: CHEPLAREN®.

2003

The BRAUN family acquires the business with an annual turnover of 600k EURO. The firm’s headquarter is relocated to Mesekenhagen close to the Baltic Sea.

2003

Sebastian F. Braun succeeds as Chief Executive Officer (CEO) of CHEPLAPHARM.
Strategy realignment expressed by the phrase Specialty pharma meets M&A competence.

2004

The products Caye® and Talidat® are acquired from Medopharm and Merck Gruppe.

2006

Acquisition of ALDACTONE®, LANITOP® and ISOMONAT® in Austria from F. Hoffmann-La Roche Basel.

2006

In April, CHEPLAPHARM takes over Ky-Cor F Dragees, Ky-Cor Novo film-coated tablets and Ky- Thermopack from Merck-Gruppe.

2007

CHEPLAPHARM achieves an annual turnover of 3 million EURO, thus doubles the previous year’s result.

2007

Takeover of Aponal® in Germany from F. Hoffmann-La Roche Basel.

2008

In May, CHEPLAPHARM purchases Aquaphor® from Eli Lilly.

2008

In June, CHEPLAPHARM obtains the rights for Gelusil Lac® from the globally operating pharmaceutical manufacturer Johnson & Johnson.

2008

CHEPLAPHARM acquires the traditional Hamburg-based company Walter Ritter GmbH & Co. KG. Consequently, the product portfolio expands with the integration of ice sprays applied especially in the treatment of sports injuries.

2008

The generated sales of nearly 8 million EURO exceed all expectations. So far, this has been the most striking increase in turnover, thus the most successful fiscal year in CHEPLAPHARM’s history.

2009

CHEPLAPHARM continues its growth strategy. Six additional products are integrated into the portfolio: the PC 30® product line from Terra Bio Chemie GmbH, Baldrian Dispert®, one of the most famous German Baldrian brands, applied for sedation and in insomnia treatment, from Vemedia Manufacturing BV, the mineral supplements CalciAPS D3, Magnesium Tonil® Mono as well as Magnesium Tonil® plus Vitamin E from ProStrakan and the pharmaceutical product Apsomol® N from Dr. Willmar Schwabe GmbH & Co. KG, Karlsruhe, Germany.

2010

September - With the acquisition of DISTRANEURIN®/HEMINEVRIN® from the Swedish-British pharmaceutical company AstraZeneca, CHEPLAPHARM expands its presence in numerous European countries. The product generates revenues in the double-digit million range and is a crucial milestone for further internationalization projects of the company.

2011

In July, CHEPLAPHARM attains the rights for a range of products of long-established company Klosterfrau GmbH: Bactisubtil® complex, Enelbin® Paste, Eryfer® 100 and Eryfer® comp as well as Thüringer Kräutertinkturen. By means of this acquisition, CHEPLAPHARM further diversifies its portfolio.

2011

Through our successful merger and acquisition strategy, CHEPLAPHARM has achieved annual double-digit growth rates since 2003. Our export ratio accounts for more than 50 percent.

2012

100 percent takeover of company shares of the in Werne-based Sanavita Pharmaceuticals.

2012

In March, CHEPLAPHARM inaugurates its new logistics center in Neukenkirchen close to Greifswald.

2012

With the takeover of VESANOID® and ROHYPNOL® from F. Hoffmann-La Roche Basel in December, CHEPLAPHARM further maintains its internationalization strategy. Consequently, we further strengthen our position as provider of branded niche products and expand our territorial presence in more than 100 countries worldwide.

2013

Bianca Y. Juha, sister of CEO Sebastian F. Braun, assumes the position of Chief Scientific Officer (CSO).

2013

In September, CHEPLAPHARM acquires Reisegold®, applied in the treatment of travel sickness, as well as Halbmond® tablets for the short-term treatment of insomnia for the German market from Teva GmbH.

2013

Along with its subsidiaries, CHEPLAPHARM attains an annual turnover of 60 million EURO. Moreover, the number of employees increases to more than 70, thus CHEPLAPHARM contributes significantly to the regional development.

2014

The takeover of all company shares from New York-based Glenwood LLC and the purchase of the US-rights for the urology product POTABA® in January represents another Milestone for CHEPLAPHARM. This acquisition is a decisive step towards the further expansion and internationalization of our branded niche products.

2014

CHEPLAPHARM acquires the worldwide rights for POTABA®.

2014

With more than 25 years of experience in the pharmaceutical business, Edeltraud Lafer joins CHEPLAPHARM as Chief Operating Officer (COO) and perfectly complements the management team.

2014

Especially our European presence is notably reinforced by acquiring the UDCA products DEURSIL®/URSOLVAN® and a number of well-established OTC products from Sanofi.

2014

At the end of the year, CHEPLAPHARM opens the doors to its representative and modern office facilities located in the business park of the Hanseatic town of Greifswald. The well-being and the related intensification of teamwork of our currently 74 employees is thus ensured.

2015

At the beginning of the year, CHEPLAPHARM purchases the logistics center from RIEMSER Arzneimittel GmbH in Greifswald.

2015

In January, we expand our product portfolio in Italy by acquiring the product Streptosil® from Boehringer Ingelheim. Also, CHEPLAPHARM secures the German-wide rights for the antihypertensive agents Dopegyt® and Pertenso®, the painkiller Octadon® and the product Cotazym®, applied against digestive disorders, from UCB Pharma GmbH.

2015

In November, CHEPLAPHARM strengthens its presence on the Italian market by the successful acquisition of the prescription drug ALDACTONE® from Sanofi. Thereby, we repeatedly reinforce our international growth strategy.

2016

At the very beginning of the year, CHEPLAPHARM takes over the product rights for ANEXATE® from F. Hoffmann-La Roche Basel. The acquisition of the product ANEXATE® allows CHEPLAPHARM to create strategically important synergies with ROHYPNOL®. This product has already been acquired in 2012, consequently, ANEXATE® perfectly supplements CHEPLAPHARM’s product portfolio in the field of sedatives. The share of exports is thus increased to approximately 80 percent.

2016

End of September, contracts for the worldwide Rights of the Antiadipositum XENICAL® and the Betablocker DILATREND® have been signed. The contract for XENICAL® came into immediate force with day of signature on September 30th. The completion of the contract for DILATREND®, in short: the closing will take place beginning of January 2017. This transaction, worth of EURO 340 million the most significant one since CHEPLAPHARM was established and it is the largest privately owned investment in the Mecklenburg-Vorpommern region.

2016

CHEPLAPHARM concludes with an annual turnover of 121 million EURO, making it one of the largest medium-sized pharmaceutical companies within Germany. The number of employees increases to 120.

2017

The Closing for DILATREND® was completed in mid-January.

2017

Based on a marketing and distribution agreement with Orexigen Therapeutics Ltd., CHEPLAPHARM markets the product MYSIMBA® in Germany, France and Austria from August 2017. This prescription drug perfectly complements the anti-obesity drug XENICAL®, which was acquired in 2016.

2017

September - More than 150 employees from twelve different nations are currently working at CHEPLAPHARM. The company thus makes an important contribution to strengthening the economic power in the region and securing valuable jobs in Mecklenburg-Vorpommern.

2017

Per 01.12.2017, CHEPLAPHARM includes the OTC product range Calcivit D®/Calcivit D® Forte of the German generics company Hexal AG in its portfolio.

2017

With annual sales of 223 million euros, CHEPLAPHARM achieved another significant increase in sales in 2017.

2018

The Closing for the antiviral agent CYMEVENE® took place on 02.01.2018 with F. Hoffmann-La Roche Ltd.

2018

Per 03.01.2018, CHEPLAPHARM takes over the products KONAKION® MM, LARIAM® and INHIBACE®/Plus from F. Hoffmann-La Roche Ltd. Thus, CHEPLAPHARM continues its expansion course.

2018

CHEPLAPHARM further enhances its portfolio in the Cardiology area. Bristol-Myers Squibb’s product SOTALEX®/SOTACOR® has both beta-blocking and antiarrhythmic properties and is thus unique. In addition, the newly acquired product now further promotes the naturally existing synergies between CHEPLAPHARM's already successfully implemented Cardiology preparations.

2018

By acquiring the worldwide rights (except USA) for the product VISUDYNE® of the Swiss Novartis Pharma AG by 15.02.2018, CHEPLAPHARM is now active in the Ophthalmology Area.

2018

Since its foundation, CHEPLAPHARM has pursued a successful and sustainable growth strategy. As this development continues in 2018, the CHEPLAPHARM team already consists of 200 employees by June.

2018

CHEPLAPHARM secures the products rights for ATACAND® and ATACAND® Plus in 28 European markets from AstraZeneca. Contract signing took place in July, Closing is determined for end of September this year.

2018

Per August, CHEPLAPHARM takes over the global rights for QUESTRAN®. With this acquisition, the company intensifies the successful cooperation with Bristol-Myers Squibb.

2018

September - CHEPLAPHARM continues its successful expansion strategy by purchasing three more global niche products: FUNGIZONE®, VEPESID® and ETOPOPHOS®. This further strengthens the partnership and the professional cooperation with Bristol-Myers Squibb.

2018

From October, the company headquarters is officially relocated from Mesekenhagen to Greifswald. Constructed in 2014, CHEPLAPHARM’s representative and modern office facilities situated in the business park Ziegelhof are at present further extended with state-of-the-art office facilities. As a result, by the end of 2019, the company has enough space for its 250 employees (per December 2018).